Morsuximide

Morsuximide

SCHEMBL357911

CC1(c2ccccc2)CC(=O)N(CN2CCOCC2)C1=O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
LMNA P02545 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
ALDH3A1 P30838 1/20 0.45
CYP2D6 P10635 1/20 0.45
HTR2C P28335 1/20 0.45
KCNH2 Q12809 1/20 0.45
HTT P42858 2/20 0.44
KDM4E B2RXH2 5/20 0.43
TSHR P16473 3/20 0.41
GLA P06280 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14037658 0.80 CYP19A1 (0.47) LMNATSHRCYP2C19
SCHEMBL24126788 0.75 ELANE (0.56) MEN1KMT2ACYP2C19GAA
SCHEMBL11882626 0.73 CYP2C19 (0.60) ALDH1A1LMNACA1CA2ALDH3A1
SCHEMBL5334247 0.73 ALDH1A1 (0.51) ALDH1A1KMT2A
SCHEMBL8293499 0.73 CYP19A1 (0.41) ALDH1A1TSHRMEN1KMT2A
SCHEMBL14359249 0.71 CYP19A1 (0.42) HTR2C
SCHEMBL14359304 0.70 HTR1A (0.44) HTR2CKDM4EMEN1KMT2AUSP2
SCHEMBL12336004 0.69 ALDH1A1 (0.59) ALDH1A1LMNACA1CA2ALDH3A1
SCHEMBL10971341 0.69 HTR1A (0.68) ALDH1A1CYP2D6HTR2CKCNH2KDM4E
Methsuximide SCHEMBL34852 0.69 CYP19A1 (0.70) ALDH1A1LMNATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8853257-B2 Succinimide derivatives as ocular hypotensive agents SHARIR MORDECHAI (IL) 2014-10-07 US claimed
EP-1951229-B1 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SHARIR MORDECHAI (IL) 2013-07-10 EP claimed
US-20120016001-A1 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SHARIR MORDECHAI (IL) 2012-01-19 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090318515-A1 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SHARIR MORDECHAI 2009-12-24 US claimed
CN-101500558-A Succinimide derivatives as ocular hypotensive agents MORDECHAI SHARIR (IL) 2009-08-05 CN claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
EP-1951229-A2 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS Sharir, Mordechai (IL) 2008-08-06 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
WO-2007057889-A2 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SHARIR MORDECHAI (IL) 2007-05-24 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
WO-2025129358-A1 STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES INTELGENX CORP. (CA) 2025-06-26 WO disclosed
CN-119823266-A Tumor microenvironment specific activation of CD47 antibodies 英脉德医疗科技(广东)有限公司 2025-04-15 CN disclosed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-4188398-A PARA-ISOPROPOXYPHENYLSUCCINIMIDE AKOPIAN NINA E 1980-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016001-A1 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SUCNR1, SYNGR2, SDHA ALDH1A1 803/4885LMNA 2568/4885CA1 650/4885
US-20090318515-A1 SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS SUCNR1, TNNI3, STIM1 ALDH1A1 975/4885LMNA 2205/4885CA1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.